173 results about "Bacteroides dorei" patented technology

The invention provides application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides dorei. Applied to animals, the bacteroides dorei can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides dorei can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

The invention relates to lactobacillus rhamnosus CCFM0528 having an inhibitory effect on alpha-glucosidase activity, the bacterial strain is preserved at the China General Microbiological Culture Collection Center (CGMCC), and the accession number is CGMCC No.7317. Cytoplasm and fermentation supernate of the CCFM0528 can respectively exhibit the inhibitory effects on the alpha-glucosidase activity, with the inhibition rates of 29.2% and 14.1% respectively. Studies show that the CCFM0528 exhibits the inhibitory effect not only on the alpha-glucosidase activity, also on glucose transport. The experimental results show that the CCFM0528 can prevent type-2 diabetes, effectively reduce fasting blood glucose and postprandial blood glucose of mice, and improve glucose tolerance of the mice. The principle may be that the CCFM0528 has inhibitory effect on the alpha-glucosidase activity and enzyme expression amount in intestinal tract, and can influence the gene expression level of glucose-transport relating protein SGLT-1 and GLUT-2.

A streptomyce shygeroscopicus (CCTCC No.M203062) able to generate glutamine transaminase wigh high output is extracted from the soil of milk cow farm through plate screening, primary fermenting, flask culture, comparing test with standard color tape, and enzyme activity test. Said glutamine transaminase is prepared by deep fermentation.

PCT No. PCT/GB96/03221 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 23, 1996 PCT Pub. No. WO97/23624 PCT Pub. Date Jul. 3, 1997The invention provides a nucleotide sequence representing a pathogenicity island found in species of pathogenic mycobacteria. The islands are shown as SEQ ID NOs: 3 and 4 and comprises several open reading frames encoding polypeptides. These polypeptides and their use in diagnosis and therapy form a further aspect of the invention.

The invention discloses a lactobacillus pentosus strain and ferment produced thereby, wherein the docket number of the R1(Lactobacillus pentosus R1) strain in the Chinese Microbiological Culture Preservation Administration Commission Common Microbiological Center is CGMCC No.0917. The pentose lactobacillus R1 strain of the invention can endure 4.0% salt solution and nitrite solution whose concentration is 80-100mg/L. The leaven prepared from the bacterial can be applied into the fermentation production of meat food.

The invention provides an antagonistic bacterium for controlling radix rehmannia root rot. The antagonistic bacterium is named as pseudomonas aeruginosa LK-12 (the Preservation No.: CGMCC 10966) after authentication. The pseudomonas aeruginosa LK-12 disclosed by the invention is obtained by screening from continuous cropping rhizosphere soil of radix rehmannia root through an agar disk diffusion method. Fusarium oxysporum and aspergillus flavus pathogenic bacteria separated from lesion parts of the radix rehmannia root have a high antagonistic effect; in the meanwhile, fusarium oxysporum, fusarium moniliforme, talaromyces sp. and other pathogenic bacteria separated from lesion parts of radix pseudostellariae also have a remarkable restriction effect and can be used for effectively controlling root rot diseases of medicinal plants comprising the radix rehmannia root to provide a strain for overcoming or relieving replant diseases of the medicinal plants. Therefore, the antagonistic bacterium is a potential biological control strain which is good in biological control effect, free of pollution as well as safe and ecological, and is wide in development and application prospects.

The invention discloses a Lactobacillus crispatus and an application. The Lactobacillus crispatusis is preserved in the China General Microbiological Culture Collection Center (CGMCC) with accession number of CGMCC NO.6406. The Lactobacillus crispatus has high acid resistance, high-yield hydrogen peroxide characteristic and vagina pathogenic bacteria growth inhibition effect, and the invention also relates to an application of the Lactobacillus crispatus LCR15 for adjusting vaginal flora, preventing and treating colpitis.

The invention discloses a pediococcus pentosaceus strain, ferment produced thereby and the use of ferment in meat product, wherein the docket number of the R9(Pediiococcus Pentosaceus I9) strain in the Chinese Microbiological Culture Preservation Administration Commission Common Microbiological Center is CGMCC No.0918. The leaven prepared from the bacterial can be applied into the fermentation production of meat food.

The invention relates to a bacterium for the production of genetically-engineered subunit oil-adjuvant vaccines against infectious bursal disease, i.e. Escherichia coli BL21/pET-28a-VP2, CCTCC No: M204038. The process for constructing the bacterium consists of inserting VP2 protein gene of the infectious bursal disease virus onto expression plasmid pET-28a to construct prokaryotic expression plasmid, then using the prokaryotic expression plasmid to transform the escherichia coli BL21, using lactose as inducer to induce Escherichia coli BL21/pET-28a-VP2 expression VP2 protein, purifying and charging oil-adjuvant to obtain the vaccines.

The present invention discloses one kind of human Ochrobactrum anthropi IBL01 (Ochrobactrum anthropi CCTCC M 206046) and its application in degrading plant stalks. Ochrobactrum anthropi IBL01 has high plant stalk degrading effect and can produce high activity cellulase, hadromse and hemicellulase. The present invention also discloses the preparation process of cellulose, xylanase, lignin peroxidase, laccase and manganese peroxidase with the human Ochrobactrum anthropi. The human Ochrobactrum anthropi of the present invention is bacterium with short growth period of about one week, and can produce fiber degrading enzyme as well as hemicellulose degrading enzyme and lignin degrading enzyme.

The invention discloses lactobacillus rhamnosus, cultivation of the lactobacillus rhamnosus and a microcapsule method. The bacterial strain is preserved in China General Microbiological Culture Collection Center (CGMCC); a registering number is CGMCC NO.3994; a Latin name of the bacterial strain is Lactobacillus rhamnosus LC-STH-13; morphological characteristics are gram-positive bacteria, short-rod bacterial thallus, no motion, no gemma, circular bacterial colony, milk white, tidy edges, smooth surfaces and protuberant cores. The invention further discloses a 16S ribosome DNA (Deoxyribose Nucleic Acid) (16S rDNA) complete sequence of the lactobacillus rhamnosus. The lactobacillus rhamnosus has the advantages that a culture is short in growth cycle, high in breeding speed and- produced lactic acid concentration. The lactobacillus rhamnosus can -colonize and survive in an intestinal tract, improves a mucosal barrier function of a gastrointestinal tract, has a function of improving the gastrointestinal tract, and restrains the colonization of harmful bacteria; and after being embedded by a microcapsule, the lactobacillus rhamnosus has stronger ability to resist the poor environment.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.

The invention relates to a porcine epidemic diarrhea virus strain MY01 and application thereof and belongs to the field of porcine epidemic diarrhea virus vaccine reagents. The porcine epidemic diarrhea virus strain MY01 is collected in China General Microbiological Culture Collection Center under CGMCC No. 11495. The porcine epidemic diarrhea virus strain MY01 is higher in pathogenicity for pigs and good in immunogenicity, a deactivated oil emulsion vaccine prepared using the strain is safe and reliable, homologous attacking protection can be provided, protection is also provided for PEDV (porcine epidemic diarrhea virus) epidemic strains, higher immunity can be generated after immunization, inoculated pigs are significantly lower in morbidity and mortality, the immunization effect is superior than that of existing commercial vaccines in the market, and the strain has the advantage of competing with like products home and abroad, can effectively prevent the prevalence and spread of porcine epidemic diarrhea virus and reduce economic cost caused by the disease and has a promising application prospect.

The invention relates to an application of anthropogenic lactobacillus casei grx12 in the aspect of chronic alcoholic liver injury. The lactobacillus casei grx12 is a probiotic strain with an obvious in-vitro antioxidant capacity, which is obtained in a separation mode from the intestinal tracts of people in the long life village of Rugao city, Jiangsu province. The lactobacillus casei grx12 is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms (CCCCM) and has the preservation number of CGMCC No.7696. The lactobacillus casei grx12 can be used for obviously decreasing the level of toxins in blood fat and blood serum of a rat with the alcoholic liver injury, decreasing the expression of liver inflammatory factors in the liver and relieving the inflammatory reaction of the liver, thereby having obvious protection functions to the chronic alcoholic liver injury.

The invention relates to a composite gene chip for detecting food pathogenic microbes, which comprises eight parallel sub-arrays constructed by detection probe groups for detecting each microbe in the eight food pathogenic microbes, blank lines are respectively arranged among the eight sub-arrays to be as intervals, thus constructing a big array; the eight food pathogenic microbes are listeria monocytogenes, comma bacillus, vibrio parahaemolyticus, salmonella, shigella, staphylococcus aureus, campylobacter jejuni and escherichia coli. The gene chip can clearly and accurately detect the species of eight target food pathogenic microbes, and also can definitely exclude other off-target microbe samples out of the eight target food pathogenic microbes. Each food pathogenic microbe detection sub-array on the chip can clearly and definitely distinguish off-target microbe samples from target microbe samples.

The invention relates to a pathogenic aeromonas hydrophila assay kit and belongs to the field of the detection of pathogenic microorganisms. A primer which is designed on the basis of a highly conserved interval of a standard strain J-1 strain 16S rDNA genome of the pathogenic aeromonas hydrophila is used for distinguishing and identifying strain characteristics of the pathogenic aeromonas hydrophila, and the amplified fragment is 685bp; and a second pair of primers which is designed according to specific proteinase aerolysin secreted by the strain is used for judging the pathogenicity of the aeromonas, and the fragment size is 301bp. The assay kit can rapidly and accurately judge the strain characteristics and pathogenicity of the strains to be tested. Comparison tests of the conventional biochemical identification method and pathogenicity identification method for experiment strains and clinical stains show that the coincidence rate of the kit is 100 percent. Evaluation tests for specificity, repeatability, sensitivity and retention period of the kit acquire ideal results.

The invention relates to a lactobacillus as well as a composition and an application thereof in treating an autoimmune disease and complications of the autoimmune disease. The composition contains separation strains of at least one strain of the following strains in effective quantity: lactobacillus paracasei GMNL-32, lactobacillus reuteri GMNL-89 or lactobacillus reuteri GMNL-263 and a pharmaceutically acceptable carrier agent. The lactobacillus and/or the composition thereof can be used for treating the autoimmune disease and the complications of the autoimmune disease.

The invention discloses saccharomyces cerevisiae 5-1 which is collected in the Guangdong Microbial Culture Collection Center, with the collection number of GDMCC No: 60243. The invention further discloses a fermentation solution, a culture and a culture dilution prepared from the saccharomyces cerevisiae 5-1. A metabolite of the saccharomyces cerevisiae 5-1 has a very strong inhibitory effect on pathogenic bacteria (escherichia coli, staphylococcus aureus and salmonella enteritidis); when the saccharomyces cerevisiae 5-1 is used as a feed additive and is added into feed for feeding animals, the disease incidence of the animals can be effectively reduced, the growth performance of the animals can be improved, and the intestinal microflora of the animals can be significantly improved, so that the saccharomyces cerevisiae 5-1 is of a great significance in development of the breeding industry.

The invention relates to the technical field of medicament, in particular to inonotus obliquus extracellular and intracellular mixing crude polysaccharide with a function of strengthening immunity, which is extracted from a submerged fermentation product of medical fungus inonotus obliquus liquid. The method comprises the following steps: taking slant strain under an asepsis condition, and inoculating the slant strain into a plate filled with fresh comprehensive solid culture medium; pumping and filtering a secondary fermentation product through primary fermentation and secondary fermentation to obtain inonotus obliquus mycelium and fermentation supernatant; and preparing the inonotus obliquus extracellular and intracellular mixing crude polysaccharide through concentration and water extraction and alcohol precipitation. In vivo experiments prove that the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can prolong the surviving time of mice hepatocellular carcinoma H22 and S180 ascites tumor mice, and can obviously improve the thymus gland index and spleen index of the mice. Furthermore, the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can obviously improve secretion of IL-2, TNF-alpha cell factors in the blood serum of the tumor-bearing mice, and can be used for preparing new immunity intensifying preparation. The invention opens up a new way for development and utilization of medical fungus resources.

The invention provides a biologic bacterial strain XY21 for preventing and treating bacterial wilt in greenhouse vegetables, and pertains to the technical field for preventing and treating diseases in crops. The XY21 is verified to be Serratia sp., the culture preservation no. is CGMCC NO.2059. The XY21 bacterial strain expresses good colonization surrounding the roots of tomatoes. After soaking the culture for 14 days, the colonized volume of the bacterial strain surrounding a root of tomato tree is 5.05 is multiplied by 10<7>cfu/g soil. If the wet bacterial strain is mixed with a lab thallus-preservation solution in a proportion of 1:40 (g/ml), the bacterial strain can be stored 2-3 years under room temperature. Tests show that, by application XY21 bacterial strain in fields, the prevention effect is 64.84% and 79.80% respectively, the outputs of the diseased fields increased respectively 31.8% and 45.8%. The invention is of high prospective to be developed into commercial live-vaccine biologic preventing preparations.

The invention discloses a porcine epidemic diarrhea virus variant strain, and an isolated culturing method and applications thereof. The porcine epidemic diarrhea virus variant strain is named as CH/ZMDZY/11, and is preserved in China General Microbiological Culture Collection Center; and preservation number is CGMCC NO.10893. The porcine epidemic diarrhea virus variant strain can be used for preparing an inactivated vaccine which can be used for preventing porcine epizootic diarrhea effectively, so that an effective control method is provided for controlling porcine epizootic diarrhea caused by porcine epidemic diarrhea virus variant strains.